ArticleRespiratory medicine case reports2017
Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia.
Article in Respiratory medicine case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 54 citations in OpenAlex.
- Severe Central Nervous System Fungal Infection Following Tirabrutinib Administration in a Patient with Refractory Primary Central Nervous System Lymphoma: A Case Report.NMC case report journal · 2026Article
- Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions.Blood reviews · 2025Review
- Clinical Mycology Today: Emerging Challenges and Opportunities.Open forum infectious diseases · 2024Review
- Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.Neurology international · 2022Review
- Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies.Journal of fungi (Basel, Switzerland) · 2021Review
- Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence.Journal of translational medicine · 2021Article
- Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.Cancer medicine · 2021Article
- Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients.Medical mycology · 2021Article
- Article
- Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.Clinical microbiology reviews · 2020Review
- [Cryptococcal meningitis in the treatment of CLL with ibrutinib: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.Frontiers in immunology · 2020Article
- Mucormycosis of the Central Nervous System.Journal of fungi (Basel, Switzerland) · 2019Review
- Antibody immunity and natural resistance to cryptococcosis.Current tropical medicine reports · 2019Article
- Cranial aspergillosis in a patient receiving ibrutinib for chronic lymphocytic leukemia.Medical mycology case reports · 2019Article
- Monocyte-to-macrophage switch reversibly impaired by Ibrutinib.Oncotarget · 2019Article
- Invasive aspergillosis complicating treatment with tyrosine kinase inhibitors.BMJ case reports · 2019Article
- Article
- CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.Oncotarget · 2018Article
- Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of invasive pulmonary aspergillosis in a patient taking ibrutinib, a Bruton's tyrosine kinase inhibitor used to treat refractory chronic lymphocytic leukemia. We hypothesize that ibrutinib promoted this infection by suppressing innate immune responses against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.